Komori
O

OncoTherapy Science,Inc.

4564PharmaceuticalsMicro cap
18JPY-14.3%
★ Watch (sign-up required)
Price history
¥18Latest-76.3%
Drag across the chart to measure the move between two points.Delayed 15 minutes · monthly closing basis
Business overview

A corporate group focused on drug discovery research and development in the oncology field and cancer precision medicine-related businesses. In drug discovery, the group conducts research and clinical trials involving small-molecule drugs, cancer peptide vaccines and antibody drugs. In its cancer precision medicine-related businesses, it provides services including large-scale genomic analysis testing, immunotherapy research and liquid biopsy, and develops new cancer gene panel tests. The group established CPM and developed its operating structure through a capital and business alliance with Theragen Bio Co., Ltd.

Recurring subjects
No threads yetThis company's filings have not been read yet. We are adding them progressively.
Companies sharing a theme
Loading
Documents
See all timely disclosuresSee all statutory filings
News
See all news
Key numbersShowing 8 of 17
PBR
3.13How many times the company's net assets? Around 1x is generally considered a benchmark.
ROE
-12.3%Earning power. A figure above 10% is generally considered good.
Dividend yield
0.0%The annual dividend as a percentage of the share price.
Market capitalization
¥7.3bnShare price × number of shares. The value of the entire company.
Equity ratio
87.2%The proportion of assets funded by money that does not have to be repaid.
Operating margin
-167.6%The percentage of revenue remaining from the company’s core business.
Revenue growth (3 years)
4.7%The average annual growth in sales over the past three years.
PSR
43.23The number of times sales are valued. Used to assess companies that are not profitable.
What to watch next
Release of a new cancer gene panel test supporting liquid biopsies and targeting insurance coverage, together with progress toward that coverage
From 2026 onward (the company has disclosed a planned release, so an update on progress in the latest fiscal period is awaited)Impact HighLikelihood Medium
Growth in orders for CPM's clinical testing and contract analysis services, including continued expansion of test items and greater clarity on overseas channels
From the next reporting period onward (quantitative order data and its impact on revenue and earnings need to be confirmed)Impact MediumLikelihood Medium
Fundraising, including the exercise of stock acquisition rights, and the resolution or reduction of uncertainty regarding the going-concern assumption
To be monitored continuously on a quarterly-to-full-year basisImpact HighLikelihood High
What to watch next
Loading
Who owns itTop holders total 12.3%
Listed holders 12.3%Everyone else 87.7%
Nakamura Yusuke (中村 祐輔)3.26%
Rakuten Securities, Inc. (shared account)2.39%
Trustee for specified securities, SMBC Trust Bank Ltd.1.90%
中鶴 修一1.52%
Nomura Securities Co., Ltd.0.99%
仲榮眞 正雄0.78%
古川 洋一0.77%
後藤 知近0.74%
Who owns it
HolderOwnership (%)
Nakamura Yusuke (中村 祐輔)3.26
Rakuten Securities, Inc. (shared account)2.39
Trustee for specified securities, SMBC Trust Bank Ltd.1.90
中鶴 修一1.52
Nomura Securities Co., Ltd.0.99
仲榮眞 正雄0.78
古川 洋一0.77
後藤 知近0.74
This company's documents
Filings
Timely disclosures
Threads